SpectraCure AB (publ) is a Swedish public limited company whose shares are listed on Nasdaq First North Premier Stockholm. Corporate governance in SpectraCure follows the Code and is thus based on principles that follow from law, listing agreements, guidelines and good practice.
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.